TWI293958B - Functional derivatives of the long pentraxin ptx3 for the preparation of an autologous vaccine for the treatment of tumours - Google Patents
Functional derivatives of the long pentraxin ptx3 for the preparation of an autologous vaccine for the treatment of tumours Download PDFInfo
- Publication number
- TWI293958B TWI293958B TW092103564A TW92103564A TWI293958B TW I293958 B TWI293958 B TW I293958B TW 092103564 A TW092103564 A TW 092103564A TW 92103564 A TW92103564 A TW 92103564A TW I293958 B TWI293958 B TW I293958B
- Authority
- TW
- Taiwan
- Prior art keywords
- ptx3
- tumor
- cells
- seq
- derivative
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 32
- 238000002360 preparation method Methods 0.000 title claims description 11
- 229940037642 autologous vaccine Drugs 0.000 title claims description 8
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 claims description 73
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 claims description 73
- 210000004881 tumor cell Anatomy 0.000 claims description 50
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 229960005486 vaccine Drugs 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 9
- 101100192405 Mus musculus Ptx3 gene Proteins 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 description 64
- 210000004027 cell Anatomy 0.000 description 40
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 19
- 239000002299 complementary DNA Substances 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 210000002706 plastid Anatomy 0.000 description 15
- 239000013598 vector Substances 0.000 description 13
- 241001529936 Murinae Species 0.000 description 12
- 210000000170 cell membrane Anatomy 0.000 description 12
- 239000002502 liposome Substances 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 239000011616 biotin Substances 0.000 description 10
- 229960002685 biotin Drugs 0.000 description 10
- 235000020958 biotin Nutrition 0.000 description 10
- 239000002738 chelating agent Substances 0.000 description 10
- 101100070731 Bradyrhizobium diazoefficiens (strain JCM 10833 / BCRC 13528 / IAM 13628 / NBRC 14792 / USDA 110) hisE2 gene Proteins 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 108700025763 PTX3 Proteins 0.000 description 8
- 108090001008 Avidin Proteins 0.000 description 7
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 235000014304 histidine Nutrition 0.000 description 6
- 150000002411 histidines Chemical class 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 101100352284 Homo sapiens PITX3 gene Proteins 0.000 description 4
- 101100031710 Homo sapiens PTX3 gene Proteins 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229910001570 bauxite Inorganic materials 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 101100518501 Mus musculus Spp1 gene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150095640 PTX3 gene Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2002RM000109A ITRM20020109A1 (it) | 2002-02-28 | 2002-02-28 | Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200303755A TW200303755A (en) | 2003-09-16 |
| TWI293958B true TWI293958B (en) | 2008-03-01 |
Family
ID=11456119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092103564A TWI293958B (en) | 2002-02-28 | 2003-02-20 | Functional derivatives of the long pentraxin ptx3 for the preparation of an autologous vaccine for the treatment of tumours |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090110666A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1478661A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005538690A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20040099291A (cg-RX-API-DMAC7.html) |
| AR (1) | AR038854A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003214645A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2475526A1 (cg-RX-API-DMAC7.html) |
| IT (1) | ITRM20020109A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04008217A (cg-RX-API-DMAC7.html) |
| PL (1) | PL372719A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI293958B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003072603A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20040858A1 (it) | 2004-04-29 | 2004-07-29 | Farma Dev S R L | Anticorpi monoclonali ibridomi metodo migliorato per determinare la proteina ptx3 e kit per detta determinazione |
| ITRM20040489A1 (it) | 2004-10-08 | 2005-01-08 | Sigma Tau Ind Farmaceuti | Pentraxina lunga ptx3 deglicosilata o desialidata. |
| JP5427415B2 (ja) * | 2006-01-24 | 2014-02-26 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | Ｆｇｆ２結合性ペプチドおよびそれらの使用 |
| US8435525B1 (en) * | 2010-04-16 | 2013-05-07 | Andrew B. Bush | FGF modulation of in vivo antibody production and humoral immunity |
| US9226960B2 (en) * | 2010-04-16 | 2016-01-05 | Andrew B. Bush | FGF modulation of in vivo antibody production and humoral immunity |
| TWI531375B (zh) | 2015-05-29 | 2016-05-01 | 國立成功大學 | 抑制癌細胞活性之短肽治療劑及含此之醫藥組成物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849478A (en) * | 1986-08-14 | 1998-12-15 | Cashman; Daniel P. | Blocked-polymerase polynucleotide immunoassay method and kit |
| US5290551A (en) * | 1990-05-08 | 1994-03-01 | Thomas Jefferson University | Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten |
| IT1298487B1 (it) * | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
| IT1317927B1 (it) * | 2000-11-03 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni. |
| IT1317930B1 (it) * | 2000-11-08 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione |
| US20020122820A1 (en) * | 2001-01-16 | 2002-09-05 | Hildebrand William H. | Soluble MHC artificial antigen presenting cells |
| US7041648B2 (en) * | 2001-08-03 | 2006-05-09 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Compositions and methods for treating female fertility |
| ES2261714T3 (es) * | 2001-08-03 | 2006-11-16 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Uso de la pentraxina larga ptx3 para tratar la infertilidad femenina. |
| ITRM20020191A1 (it) * | 2002-04-08 | 2003-10-08 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att |
| US20040137544A1 (en) * | 2002-10-31 | 2004-07-15 | Roberto Latini | PTX3 as an early prognostic indicator of cardiovascular and cerebrovascular pathologies |
| ITRM20030596A1 (it) * | 2003-12-23 | 2005-06-24 | Sigma Tau Ind Farmaceuti | Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3. |
| US20070023879A1 (en) * | 2005-07-29 | 2007-02-01 | Vinayak Pandey | Single unit heat sink, voltage regulator, and package solution for an integrated circuit |
-
2002
- 2002-02-28 IT IT2002RM000109A patent/ITRM20020109A1/it unknown
-
2003
- 2003-02-20 TW TW092103564A patent/TWI293958B/zh active
- 2003-02-25 EP EP03710225A patent/EP1478661A2/en not_active Withdrawn
- 2003-02-25 US US10/506,046 patent/US20090110666A1/en not_active Abandoned
- 2003-02-25 AU AU2003214645A patent/AU2003214645A1/en not_active Abandoned
- 2003-02-25 CA CA002475526A patent/CA2475526A1/en not_active Abandoned
- 2003-02-25 MX MXPA04008217A patent/MXPA04008217A/es unknown
- 2003-02-25 JP JP2003571309A patent/JP2005538690A/ja active Pending
- 2003-02-25 WO PCT/IT2003/000104 patent/WO2003072603A2/en not_active Ceased
- 2003-02-25 KR KR10-2004-7013464A patent/KR20040099291A/ko not_active Ceased
- 2003-02-25 PL PL03372719A patent/PL372719A1/xx unknown
- 2003-02-27 AR ARP030100642A patent/AR038854A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200303755A (en) | 2003-09-16 |
| WO2003072603A2 (en) | 2003-09-04 |
| ITRM20020109A1 (it) | 2003-08-28 |
| US20090110666A1 (en) | 2009-04-30 |
| MXPA04008217A (es) | 2004-11-26 |
| AU2003214645A1 (en) | 2003-09-09 |
| AU2003214645A8 (en) | 2003-09-09 |
| PL372719A1 (en) | 2005-07-25 |
| WO2003072603A3 (en) | 2004-03-18 |
| EP1478661A2 (en) | 2004-11-24 |
| WO2003072603A9 (en) | 2004-10-07 |
| CA2475526A1 (en) | 2003-09-04 |
| AR038854A1 (es) | 2005-01-26 |
| KR20040099291A (ko) | 2004-11-26 |
| JP2005538690A (ja) | 2005-12-22 |
| ITRM20020109A0 (it) | 2002-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4480580B2 (ja) | Ｗｔ１置換型ペプチド | |
| JP4886507B2 (ja) | Ｗｔ１由来の癌抗原ペプチド | |
| TW510921B (en) | Modified TNFα molecules, DNA encoding such modified TNFα molecules and vaccines comprising such modified TNFα molecules and DNA | |
| JP5230891B2 (ja) | 抗原特異的ｔ細胞の新規な誘導方法 | |
| JP2024036364A (ja) | Ｉ型インターフェロン遺伝子を刺激するための方法及びカチオン性脂質を含む組成物 | |
| RU2747296C2 (ru) | Вакцинация с использованием альфа3 домена mica/b для лечения рака | |
| CN1678338A (zh) | 调控调节性t细胞活性的方法及组合物 | |
| US20230218730A1 (en) | Vaccine therapy for ran protein diseases | |
| US20160296620A1 (en) | Hmgn polypeptides as immune enhancers and hmgn antagonists as immune suppressants | |
| KR20110030554A (ko) | 항아밀로이드 면역원성 조성물, 방법 및 용도 | |
| JP4261439B2 (ja) | 免疫調節能力の増加されたＣｐＧオリゴデオキシヌクレオチド変形体 | |
| JP4033497B2 (ja) | ワクチン製剤 | |
| JP4138073B2 (ja) | ヒト癌退縮抗原タンパク質 | |
| TWI293958B (en) | Functional derivatives of the long pentraxin ptx3 for the preparation of an autologous vaccine for the treatment of tumours | |
| CN101072875A (zh) | 新型癌抗原肽及其用途 | |
| US20030215460A1 (en) | Methods and compositions for inducing an immune response | |
| CN113227121A (zh) | 通过特异性结合至靶细胞具有增强的多种免疫功能的嵌合抗原及其用途 | |
| EP1240317B1 (en) | Nucleic acid vaccination | |
| CA2588573C (en) | Immunotherapeutic formulations to generate autoantibodies capable to avoid the binding of interleukin-2 to its receptor their use in the treatment of cancer | |
| WO2007081301A2 (en) | Methods and compositions related to the identification of a novel il-12 inducing protein isolated from toxoplasma gondii | |
| JP4231284B2 (ja) | Ｓｙｔ−ｓｓｘ改変ペプチド | |
| TWI278320B (en) | A complex immunity gene medicine composition for inhibiting tumor cell | |
| JP2000116383A (ja) | ヒト癌退縮抗原タンパク質 | |
| KR20050052499A (ko) | 자가 그렐린에 대한 면역화 | |
| HK1154591A (en) | Anti-amyloid immunogenic compositions, methods and uses |